Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 10 | 2023 | 643 | 1.820 |
Why?
|
| Hypoglycemic Agents | 9 | 2023 | 160 | 1.590 |
Why?
|
| Insulin | 5 | 2012 | 236 | 0.940 |
Why?
|
| Sulfonylurea Compounds | 2 | 2019 | 12 | 0.770 |
Why?
|
| Metformin | 2 | 2019 | 65 | 0.710 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 15 | 0.700 |
Why?
|
| Cholesterol | 3 | 2013 | 205 | 0.480 |
Why?
|
| Insulin Resistance | 3 | 2012 | 184 | 0.450 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 23 | 0.440 |
Why?
|
| Hyperlipidemias | 1 | 2013 | 36 | 0.440 |
Why?
|
| Thiazolidinediones | 2 | 2011 | 50 | 0.440 |
Why?
|
| Insurance, Health | 1 | 2013 | 126 | 0.410 |
Why?
|
| Pyrazines | 1 | 2011 | 24 | 0.400 |
Why?
|
| Triazoles | 1 | 2011 | 86 | 0.380 |
Why?
|
| Minority Groups | 2 | 2012 | 596 | 0.370 |
Why?
|
| Poverty | 1 | 2012 | 348 | 0.350 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 404 | 0.320 |
Why?
|
| Treatment Outcome | 6 | 2023 | 1369 | 0.310 |
Why?
|
| Middle Aged | 10 | 2023 | 10129 | 0.300 |
Why?
|
| Blood Glucose | 4 | 2020 | 353 | 0.300 |
Why?
|
| Cholesterol, LDL | 2 | 2006 | 68 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 864 | 0.270 |
Why?
|
| Atherosclerosis | 1 | 2006 | 134 | 0.250 |
Why?
|
| Lipids | 1 | 2006 | 235 | 0.250 |
Why?
|
| Aged | 6 | 2021 | 6741 | 0.250 |
Why?
|
| Medicine, Ayurvedic | 1 | 2004 | 9 | 0.250 |
Why?
|
| Adult | 9 | 2023 | 11712 | 0.250 |
Why?
|
| Phytotherapy | 1 | 2004 | 81 | 0.230 |
Why?
|
| Hypoglycemia | 1 | 2023 | 17 | 0.230 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 227 | 0.220 |
Why?
|
| Humans | 17 | 2023 | 37093 | 0.210 |
Why?
|
| Nutrition Surveys | 2 | 2017 | 242 | 0.200 |
Why?
|
| Female | 10 | 2023 | 20969 | 0.200 |
Why?
|
| Glycemic Index | 1 | 2020 | 8 | 0.180 |
Why?
|
| Double-Blind Method | 4 | 2023 | 286 | 0.180 |
Why?
|
| Male | 9 | 2023 | 20025 | 0.180 |
Why?
|
| Treatment Failure | 1 | 2019 | 64 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 68 | 0.170 |
Why?
|
| Antimalarials | 1 | 2019 | 55 | 0.170 |
Why?
|
| Prospective Studies | 2 | 2020 | 1378 | 0.160 |
Why?
|
| Adolescent | 4 | 2013 | 5363 | 0.150 |
Why?
|
| Young Adult | 3 | 2013 | 4268 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2019 | 661 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 485 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2003 | 664 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 2721 | 0.120 |
Why?
|
| Testosterone | 2 | 2006 | 193 | 0.110 |
Why?
|
| Glucagon-Like Peptides | 2 | 2023 | 3 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2012 | 136 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 225 | 0.110 |
Why?
|
| Cultural Characteristics | 1 | 2012 | 125 | 0.100 |
Why?
|
| Exercise | 1 | 2017 | 613 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2013 | 455 | 0.100 |
Why?
|
| Los Angeles | 1 | 2012 | 380 | 0.100 |
Why?
|
| United States | 3 | 2017 | 4223 | 0.100 |
Why?
|
| Perception | 1 | 2012 | 195 | 0.100 |
Why?
|
| Educational Status | 1 | 2012 | 313 | 0.100 |
Why?
|
| Insulin, Long-Acting | 1 | 2010 | 3 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 9 | 0.100 |
Why?
|
| Cities | 1 | 2010 | 63 | 0.090 |
Why?
|
| Risk Factors | 2 | 2012 | 3562 | 0.090 |
Why?
|
| Logistic Models | 1 | 2012 | 923 | 0.090 |
Why?
|
| Weight Gain | 1 | 2010 | 136 | 0.090 |
Why?
|
| Nicotine | 1 | 2012 | 257 | 0.090 |
Why?
|
| Apolipoproteins B | 2 | 2006 | 18 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2013 | 854 | 0.080 |
Why?
|
| Cholesterol, HDL | 2 | 2006 | 97 | 0.080 |
Why?
|
| Triglycerides | 2 | 2006 | 138 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2010 | 225 | 0.080 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 24 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 41 | 0.070 |
Why?
|
| Demography | 1 | 2006 | 175 | 0.070 |
Why?
|
| Weight Loss | 1 | 2006 | 131 | 0.060 |
Why?
|
| Smoking | 1 | 2012 | 940 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2006 | 534 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 68 | 0.060 |
Why?
|
| Annexin A2 | 1 | 2004 | 6 | 0.060 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 15 | 0.060 |
Why?
|
| Chromans | 1 | 2004 | 15 | 0.060 |
Why?
|
| Muscle Proteins | 1 | 2004 | 51 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2004 | 156 | 0.060 |
Why?
|
| Adipocytes | 1 | 2004 | 58 | 0.060 |
Why?
|
| Benzothiazoles | 1 | 2023 | 21 | 0.060 |
Why?
|
| Cytokines | 1 | 2006 | 602 | 0.050 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 5 | 0.050 |
Why?
|
| Body Weight | 1 | 2023 | 434 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2006 | 2026 | 0.050 |
Why?
|
| Fructosamine | 1 | 2020 | 2 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2021 | 295 | 0.050 |
Why?
|
| Quality of Life | 1 | 2004 | 481 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2020 | 50 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 91 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 739 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 974 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2012 | 13 | 0.030 |
Why?
|
| Hypogonadism | 1 | 2012 | 21 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 2012 | 63 | 0.030 |
Why?
|
| HIV Infections | 1 | 2006 | 2303 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2006 | 13 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2006 | 40 | 0.020 |
Why?
|
| Thrombosis | 1 | 2006 | 63 | 0.020 |
Why?
|
| California | 1 | 2006 | 476 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2004 | 59 | 0.010 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2004 | 14 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 610 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 77 | 0.010 |
Why?
|
| Comorbidity | 1 | 2006 | 623 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 207 | 0.010 |
Why?
|
| Biological Transport | 1 | 2004 | 185 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 252 | 0.010 |
Why?
|
| Apolipoproteins C | 1 | 2002 | 3 | 0.010 |
Why?
|
| Apolipoprotein C-III | 1 | 2002 | 5 | 0.010 |
Why?
|
| Glucose | 1 | 2004 | 230 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 15081 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 618 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2002 | 116 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2002 | 149 | 0.010 |
Why?
|
| Estradiol | 1 | 2002 | 262 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 5913 | 0.010 |
Why?
|